Ionis Pharmaceuticals, Inc. (BMV:IONS)
| Market Cap | 84.36B -61.6% |
| Revenue (ttm) | 17.31B -0.7% |
| Net Income | -9.85B |
| EPS | -63.56 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50 |
| Open | 960.00 |
| Previous Close | 1,010.00 |
| Day's Range | 960.00 - 960.00 |
| 52-Week Range | 960.00 - 1,180.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 9, 2026 |
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ... [Read more]
Financial Performance
In 2025, Ionis Pharmaceuticals's revenue was $943.71 million, an increase of 33.83% compared to the previous year's $705.14 million. Losses were -$381.39 million, -15.97% less than in 2024.
Financial numbers in USD Financial StatementsNews
Ionis Pharmaceuticals price target lowered to $65 from $80 at Guggenheim
Guggenheim analyst Debjit Chattopadhyay lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $65 from $80 and keeps a Buy rating on the shares. Cutting the FY26 outlook by…
Ionis Pharmaceuticals Transcript: Jefferies Global Healthcare Conference
TRYNGOLZA is building a new sHTG market, with launch priorities focused on high-risk patients, physician experience and smoother access. By end-September, 34% of commercial lives were covered and more than 1,500 prescribers had written prescriptions.
Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer's disease
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared new data from the Phase 2 CELIA study showing increasing clinical benefit...
Ionis Pharmaceuticals announces EC approval for Tryngolza
Ionis Pharmaceuticals (IONS) announced that the European Commission, or EC, has approved Tryngolza as an adjunct to diet, in combination with other lipid-lowering therapies, for the treatment of adult...
TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the European Commission (EC) has approved TRYNGOLZA™ (olezarsen) as an adjunct to diet, in combinatio...
Ionis Pharmaceuticals Transcript: UBS Global Biopharma Conference 2026
TRYNGOLZA’s early launch is progressing as HCPs gain experience, with label-wide payer coverage and a $3B+ U.S. peak-sales outlook. Pipeline milestones include ION775 Phase III planning in 2027 and Angelman syndrome data expected in H2 2027.
Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors
NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS).
Ionis Pharmaceuticals presents new long-term data on DAWNZERA
Ionis Pharmaceuticals (IONS) announced new long-term data for DAWNZERA, the first and only RNA-targeted medicine for hereditary angioedema, to be presented at the 2026 American College of Allergy, Ast...
Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new long-term data for DAWNZERA® (donidalorsen), the first and only RNA-targeted medicine for hereditary a...
Ionis Pharmaceuticals price target lowered to $70 from $85 at Barclays
Barclays lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $70 from $85 and keeps an Overweight rating on the shares. The firm updated the company’s model post the…
Ionis Pharmaceuticals price target lowered to $60 from $87 at Piper Sandler
Piper Sandler lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $60 from $87 and keeps an Overweight rating on the shares.
Ionis Pharmaceuticals price target lowered to $80 from $95 at Wells Fargo
Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $80 from $95 and keeps an Overweight rating on the shares. Tryngolza launch was more…
Ionis Pharmaceuticals price target lowered to $70 from $100 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $70 from $100 and keeps a Buy rating on the shares post the Q3 report.
Ionis Pharmaceuticals price target lowered to $41 from $58 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $41 from $58 and keeps a Neutral rating on the shares. Ionis faces near-term specialty cardiovascular launch headwinds…
Ionis Pharmaceuticals price target lowered to $63 from $91 at BofA
BofA lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $63 from $91 and keeps a Buy rating on the shares. While it is “not a surprise” that Ionis…
Ionis Pharmaceuticals price target lowered to $72 from $85 at Canaccord
Canaccord lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $72 from $85 and keeps a Buy rating on the shares. The firm said 3Q had overall top-/bottom-line beats,…
Ionis Pharmaceuticals price target lowered to $81 from $88 at UBS
UBS lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $81 from $88 and keeps a Buy rating on the shares. Tryngolza sales significantly missed expectations, prompting a 50%…
Ionis Pharmaceuticals price target lowered to $70 from $85 at Oppenheimer
Oppenheimer analyst Justin Kim lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $70 from $85 and keeps an Outperform rating on the shares. The firm notes the company…
Ionis Pharmaceuticals price target lowered to $53 from $84 at TD Cowen
TD Cowen lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $53 from $84 and keeps a Buy rating on the shares. The firm said Tryngolza is off to…
Ionis Pharmaceuticals price target lowered to $75 from $104 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $75 from $104 and keeps an Overweight rating on the shares.
Ionis Pharmaceuticals price target lowered to $60 from $85 at RBC Capital
RBC Capital lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $60 from $85 and keeps an Outperform rating on the shares. The company’s Q3 result was a disappointing…
IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals
Ionis topped third-quarter revenue estimates with roughly $243 million in sales, yet IONS shareholders took losses as the same report showed a $110 million net loss and a more than 50% cut to TRYNGOLZ...
Ionis to present at upcoming investor conferences
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: UBS Global Bioph...
Ionis Pharmaceuticals falls -27.3%
Ionis Pharmaceuticals (IONS) is down -27.3%, or -$10.75 to $28.67.
Ionis Pharmaceuticals (IONS) Shares Drop Following Sharp Reduction in TRYNGOLZA Sales Forecast – Kehoe Law Firm, P.C. Investigating
Kehoe Law Firm investigating potential securities claims on behalf of Ionis (IONS) investors following reduced TRYNGOLZA sales guidance and stock decline